ivabradine (Corlanor, Lancora)
Jump to navigation
Jump to search
Indications
- treatment of chronic heart failure
- FDA-approved for reducing risk of hospitalization from worsening chronic heart failure[3]
- indicated for stable patients with systolic heart failure & a heart rate of > 70/minute despite maximally tolerated beta-blockers[3][4]
- treatment of postural orthostatic tachycardia syndrome
- no benefit for stable coronary artery disease without heart failure[2]
* no advantages over commonly used beta-blockers[5]
Contraindications
- not useful in patients with atrial fibrillation[7]
Adverse effects
Mechanism of action
- inhibits atrial sinus node & slows heart rate
More general terms
References
- ↑ Swedberg K et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010 Aug 29 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20801500 <Internet> http://dx.doi.org/10.1016/S0140-6736(10)61198-1
Bohm M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010 Aug 29 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20801495 <Internet> http://dx.doi.org/10.1016/S0140-6736(10)61259-7 - ↑ 2.0 2.1 Fox K et al for the SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014 Aug 31; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25176136 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1406430
Ohman EM and Alexander KP. The challenges with chronic angina. N Engl J Med 2014 Aug 31 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25176137 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1409369 - ↑ 3.0 3.1 3.2 Medscape Oncology FDA Approves Ivabradine (Corlanor) for Chronic HF. http://www.medscape.com/viewarticle/843242
- ↑ 4.0 4.1 Yancy CW et al Heart Failure Focused Update on Pharmacological Therapy. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation 2016 134: <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27208050 <Internet> http://circ.ahajournals.org/content/early/2016/05/18/CIR.0000000000000435.full.pdf+html
J Am Coll Cardiol. 2016 May 17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27216111 Free Article
Antman EM et al Editorial: ACC/AHA/HFSA and ESC Updated Heart Failure Guideline Collaboration. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. Circulation 2016 134: <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27216110 Free Article <Internet> http://circ.ahajournals.org/content/early/2016/05/18/CIR.0000000000000436.full.pdf+html - ↑ 5.0 5.1 5.2 5.3 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- ↑ Taub PR, Zadourian A, Lo HC et al. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2021 Feb 23; 77:861. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33602468 https://www.sciencedirect.com/science/article/abs/pii/S0735109720381316
- ↑ 7.0 7.1 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022